Clover Biopharmaceuticals, a Chengdu biotech startup, completed a $9.5M Series A financing led by Tianhe Life Sciences Venture Fund.
December 14, 2017 -- Clover Biopharmaceuticals, Inc. a Chengdu biotech startup, completed a $9.5 million Series A financing led by Tianhe Life Sciences Venture Fund. Clover is developing a portfolio of novel biologic and differentiated biosimilar drug candidates. The company in-licensed rights to GenHunter Trimer-Tag© technology, which it uses to discover novel molecules for autoimmune diseases and cancer. It has also built a cGMP manufacturing capability for biologics, and expects to begin two clinical programs next year. The company plans to bring its novel, affordable drugs to China and global markets.
